BACKGROUND: Single antigen beads (SAB) are used for monitoring HLA antibodies in pretransplant and posttransplant patients despite the discrepancy between virtual and actual crossmatch results and transplant outcomes. This discrepancy can be attributed to the presence of conformational variants of HLA-I on SAB, assessment of which would increase the concordance between SAB and flow cytometry crossmatch (FCXM) results, thus enabling improved organ accessibility for the waiting list patients and a better prediction of antibody-mediated rejection. METHODS: The conformational variants were examined on HLA-I beads, iBeads, acid-/alkali-treated beads, and T cells using HLA-I monoclonal antibodies (W6/32, TFL-006, and heavy chain (HC)-10). RESULTS: The affinity of the monoclonal antibodies against HLA-I beads confirmed the presence and heterogeneous density of peptide-associated β2-microglobulin-associated HLA HC (pepA-β2aHC), peptide-free-β2aHC (pepF-β2aHC), and β2-free HC (β2fHC) on every single antigen-coated bead. In contrast, iBeads harbor a high density of pepA-β2aHC, low density of pepF-β2aHC, and are lacking β2fHC. The FCXM analyses confirmed the prevalence of pepA-β2aHC, but not pepF-β2aHC or β2fHC on resting T cells. CONCLUSIONS: The strength of a donor-specific antibody should be assessed with a bead-specific mean fluorescence intensity cutoff based on TFL-006 reactivity against HLA-I beads, and HC-10 against iBeads, where the β2fHC or pepF-β2aHC normalized donor-specific antibody level would reveal the true anti-pepA-β2aHC reactivity associated with positive FCXM.
BACKGROUND: Single antigen beads (SAB) are used for monitoring HLA antibodies in pretransplant and posttransplant patients despite the discrepancy between virtual and actual crossmatch results and transplant outcomes. This discrepancy can be attributed to the presence of conformational variants of HLA-I on SAB, assessment of which would increase the concordance between SAB and flow cytometry crossmatch (FCXM) results, thus enabling improved organ accessibility for the waiting list patients and a better prediction of antibody-mediated rejection. METHODS: The conformational variants were examined on HLA-I beads, iBeads, acid-/alkali-treated beads, and T cells using HLA-I monoclonal antibodies (W6/32, TFL-006, and heavy chain (HC)-10). RESULTS: The affinity of the monoclonal antibodies against HLA-I beads confirmed the presence and heterogeneous density of peptide-associated β2-microglobulin-associated HLA HC (pepA-β2aHC), peptide-free-β2aHC (pepF-β2aHC), and β2-free HC (β2fHC) on every single antigen-coated bead. In contrast, iBeads harbor a high density of pepA-β2aHC, low density of pepF-β2aHC, and are lacking β2fHC. The FCXM analyses confirmed the prevalence of pepA-β2aHC, but not pepF-β2aHC or β2fHC on resting T cells. CONCLUSIONS: The strength of a donor-specific antibody should be assessed with a bead-specific mean fluorescence intensity cutoff based on TFL-006 reactivity against HLA-I beads, and HC-10 against iBeads, where the β2fHC or pepF-β2aHC normalized donor-specific antibody level would reveal the true anti-pepA-β2aHC reactivity associated with positive FCXM.
Authors: Arend Mulder; Chantal Eijsink; Michel G D Kester; Marry E I Franke; Marrie J Kardol; Mirjam H M Heemskerk; Cees van Kooten; Frank A Verreck; Jan Wouter Drijfhout; Frits Koning; Ilias I N Doxiadis; Frans H J Claas Journal: J Immunol Date: 2005-11-01 Impact factor: 5.422
Authors: William F Hawse; Brian E Gloor; Cory M Ayres; Kevin Kho; Elizabeth Nuter; Brian M Baker Journal: J Biol Chem Date: 2013-07-08 Impact factor: 5.157
Authors: Shalini Pereira; Susan Perkins; Jar-How Lee; Wayne Shumway; William LeFor; Mayra Lopez-Cepero; Cynthia Wong; Amy Connolly; Jane C Tan; F Carl Grumet Journal: Hum Immunol Date: 2011-03-09 Impact factor: 2.850
Authors: Luis E Morales-Buenrostro; Paul I Terasaki; Lluvia A Marino-Vázquez; Jar-How Lee; Nadim El-Awar; Josefina Alberú Journal: Transplantation Date: 2008-10-27 Impact factor: 4.939
Authors: Matthias Niemann; Benedict M Matern; Eric Spierings; Stefan Schaub; Gideon Hönger Journal: Front Immunol Date: 2021-12-21 Impact factor: 7.561
Authors: Mepur H Ravindranath; Narendranath M Ravindranath; Senthamil R Selvan; Edward J Filippone; Carly J Amato-Menker; Fatiha El Hilali Journal: Vaccines (Basel) Date: 2022-02-21
Authors: Yue Gu; Robynne W K Koh; May Ling Lai; Denise Pochinco; Rachel Z C Teo; Marieta Chan; Tanusya M Murali; Chong Wai Liew; Yee Hwa Wong; Nicholas R J Gascoigne; Kathryn J Wood; Julien Lescar; Peter Nickerson; Paul A MacAry; Anantharaman Vathsala Journal: Sci Rep Date: 2020-10-27 Impact factor: 4.379